AI + Microecological Therapy Blockbuster: Unknown Jun Acquires Ulcerative Colitis Clinical Pipeline

A few days ago, the industry-leading AI+ innovative therapy microecological drug research and development company Wuweijun announced that it has acquired the clinical stage drug pipeline M201 project from Assembly Biosciences, Inc.

The M201 program is designed for patients with mild to moderate ulcerative colitis

According to Unknown Jun, M201 will be further developed using its drug R&D platform driven by artificial intelligence and big data

"Unknown Jun has always been committed to developing more advanced treatment methods for ulcerative colitis," said Tan Xian, co-founder and CEO of Unknown Jun.

It is reported that Unknown Jun has built a top-notch "AI+BT" platform that is scarce in the industry, combining artificial intelligence, biological information analysis and intestinal microecological technology to achieve efficient drug development of "dry and wet combination"

Through this acquisition, Unknown Jun has harvested the third microecological drug pipeline that has entered the clinical stage

Since its establishment in 2017, Unknown Jun has expanded the company's operations to 7 cities around the world; recently, Unknown Jun has set up its US headquarters in Cambridge, Massachusetts, which has both corporate operations and laboratory functions

About unknown gentleman

Founded in 2017, Shenzhen Unknown Jun Biotechnology Co.

Contacts

Hermione He

Chief Operating Officer Unknown Jun (US) Chief Operating Officer

hermionehe@xbiome.